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Background/aim: Interferon-induced helicase (IFIH1) is a gene locus that has been recently defined as a candidate for susceptibility
to generalized vitiligo (GV). The objectives of this study were to assess the association of IFIH1 gene, rs2111485, and rs1990760 singlenucleotide polymorphisms (SNP) with susceptibility to GV and the autoimmune diseases accompanying GV.
Materials and methods: We prospectively studied GV patients and frequency-matched healthy controls by age and sex. The genotypes
of the participants were determined for rs1990760 and rs2111485 SNPs of IFIH1. Dominant, recessive, and additive models were
evaluated for each SNP adjusted for age and sex.
Results: The patients and their controls were observed to be in the Hardy–Weinberg equilibrium for SNP1 (2q24.2, rs1990760, IFIH1,
T/C) and SNP2 (2q24.2, rs2111485, IFIH1, G/A), respectively (all P > 0.7). For SNP1, every T allel addition was significantly associated
with 1.53 times protectiveness in terms of vitiligo risk (P = 0.033). As for SNP2, every G allel addition was associated with 1.42 times
protectiveness, close to statistical significance (P = 0.100).
Conclusions: We detected that for SNP1, each T allel and for SNP2, each G allel are protective in terms of vitiligo development. Hereby,
we confirmed that IFIH1 gene locus has a role in GV susceptibility.
Key words: Vitiligo, single nucleotide polymorphism, genes

1. Introduction
Vitiligo is a common acquired disorder in which
depigmented skin results from destruction of melanocytes
(1). Generalized vitiligo (GV), the prevalent form of the
disease, results from the interaction among multiple
genetic and environmental factors that ultimately cause
autoimmune destruction of melanocytes in affected
regions (2). Vitiligo occurrence in other members of
patients’ families confirms the role of genetic factors in
pathogenesis of the disease (3).
Vitiligo pathogenesis involves innate immune
responses triggered by environmental and cell-intrinsic
factors that cause melanocyte stress. Damaged melanocytes
release damage-associated molecular patterns (DAMPs),
such as reactive oxygen species (ROS) and heat shock
proteins (HSPs), that function as ligands for innate pattern
recognition receptors (PRRs). Activation of PRRs by
stress-induced DAMPs initiate inflammation that drives
melanocyte destruction (4).

Vitiligo often accompanies other autoimmune diseases,
including type 1 diabetes mellitus (T1D), autoimmune
thyroid disease, rheumatoid arthritis (RA), alopecia areata,
adult-onset autoimmune diabetes mellitus, inflammatory
bowel disease, pernicious anemia, autoimmune gastritis,
psoriasis, systemic lupus erythematosus (SLE), discoid
lupus, Guillain–Barré syndrome, myasthenia gravis,
Addison’s disease, linear morphea, and Sjögren’s syndrome
(2,5). This epidemiologic association can be seen also in
the close relatives of GV patients, proposing that common
genes lie behind predisposition to this group of diseases
(6).
IFIH1 (interferon-induced helicase), also called MDA5 (melanoma-differentiation-associated gene 5), is a locus
in the innate immunity viral RNA receptor gene region on
chromosome (2q24.3) (Gene ID: 64135) (7). The natural
immune system senses viral infection by distinguishing
a variety of viral components and thus initiates antiviral
responses (8). IFIH1 encodes an RNA helicase that

* Correspondence: t_duru@hotmail.com

206

This work is licensed under a Creative Commons Attribution 4.0 International License.

ONAN et al. / Turk J Med Sci
mediates the natural immune system’s antiviral interferon
response through viral double-stranded (ds)RNA
recognition (8,9). By functioning as a PRR, IFIH1 also
activates innate immune responses on binding DAMPs
that are not associated with pathogens, hereby giving way
to autoimmune triggering (10).
IFIH1 has been reported to be associated with several
autoimmune diseases such as T1D, Graves’ disease,
multiple sclerosis, psoriasis, and possibly lupus (5,7,11–
16); it has also been recently defined as a candidate
for susceptibility to GV (10,17). No population-based,
randomized controlled study has been reported since then
to confirm the association between IFIH1 and vitiligo.
The research question of this study is whether IFIH1
gene locus plays a role in GV susceptibility. Accordingly,
we aimed to investigate the association of IFIH1 gene
polymorphisms with susceptibility of GV and the
autoimmune diseases accompanying GV.
2. Materials and methods
This gene analysis study was designed as a case-control
study. Institutional Ethics Committee of our research
hospital approved the project (757/2014) and informed
consent was obtained from the subjects. We prospectively
studied GV patients and frequency-matched healthy
controls by age and sex in the Turkish population. The
subjects were selected consecutively from the patients
who were admitted to the Dermatology department of our
hospital between January 2014 and August 2015. Patients
who did not meet the term of nonsegmental vitiligo in
the dermatological examination and controls with any
autoimmune disease diagnosis and family history of
vitiligo were excluded from the study.
The patient group was questioned for skin phototype,
age of vitiligo onset, disease duration and activity, treatment
history, and repigmentation history (spontaneous/after
treatment). Any other concomitant autoimmune disease,
family history of vitiligo, or any other autoimmune disease
were also recorded.
2.1. The analysis of rs2111485 and rs1990760 singlenucleotide polymorphisms (SNPs)
2.1.1. DNA isolation
Blood samples were collected from the patients and the
controls into EDTA tubes in order to isolate the genomic
DNA. The samples were transferred to a molecular
analysis laboratory where the DNA isolation was carried
out by using InvitrogenIprep® isolation system. The quality
and the quantity of the isolated DNA was detected with
Nanodrop® spectrophotometer. DNA samples were stored
in eppendorf tubes that do not contain DNAse and RNAse
until the time of analysis in a calibrated deep-freezer at
−200 °C.

2.1.2. Amplification of the target regions
rs2111485 and rs1990760 SNPs were prepared and ordered
from the ABI File Builder Software® system. Genotyping
solution was diluted 20X with 1XTE buffer in order to
form the study solution which was then stored at −200
°C. The analysis was performed with ABI Fast 7500 HT
real-time PCR system by using a plate of 96 wells. For
the amplification, 11.25 µL of genomic DNA was mixed
with TaqMan® Universal PCR Master Mix (2X), 12.5 µL
of No AmpErase UNG, and 1.25 µL of 20X workingstock
of SNP GenotypingAssay per each well and was amplified
in a thermal cycler. Thermal cycler conditions for
amplification: enzyme activation at 95 °C for 10 min; 40
cycles of denaturation at 92 °C for 15 s; then 40 cycles of
annealing and extension at 60 °C for 1 min.
2.1.3. Allelic discrimination and analysis
After the PCR amplification was completed, the genotypes
of the participants in terms of rs2111485 and rs1990760
SNPs of IFIH1 locus were determined by ABI 7500 Fast
analysis system.
The results were analyzed by a clinical and biochemical
geneticist. A precise result was obtained for at least one
of the SNPs in 127 of the patients and 111 of the controls.
The missing results were due to amplification failure in
PCR, probably resulting from unmatched primers due to
a different underlying SNP or low-quality DNA. With the
completed number of patients, the study has 80% power to
detect an odds ratio of 2.2 for SNP1 and 2.4 for SNP2 with
5% type-I error level as statistically significant.
2.2. Statistical analysis
IBM SPSS version 21 was used for data analysis.
Descriptive statistics were presented by frequencies,
percentages, and median (min, max) values. The patients
and their controls were tested for the Hardy–Weinberg
equilibrium for SNP1 (2q24.2, rs1990760, IFIH1, T/C)
and SNP2 (2q24.2, rs2111485, IFIH1, G/A), respectively.
Dominant (C/C, C/T-T/T; A/A, A/G-G/G), recessive
(C/C-C/T, T/T; A/A-A/G, G/G), and additive models were
evaluated for each SNP, with adjustment for age and sex
using logistic regression. In the additive model, additional
protectiveness of each T allele for SNP1 and each G allele
for SNP2 were estimated. The association between patient
characteristics and each SNP was investigated using Chisquare test. A P-value of less than 0.05 was considered to
indicate statistical significance.
3. Results
There was no difference in terms of mean ages between
the vitiligo patient group (40.6 ± 16.5) (range: 13–82)
and the control group (43.0 ± 17.0) (range: 10–84) (P =
0.262). Similarly, no difference was detected in terms of
sex between the vitiligo patient group [71 females (55.9%);
56 males (44.1%)] and the control group [64 females
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(57.7%); 47 males (42.3%)] (P = 0.791). The mean age of
vitiligo onset was 33.5 ± 17.2 years and the mean of disease
duration was 7.1 ± 9.8 years in the patient group (Table 1).
When we evaluated the skin phototype of the vitiligo
patients, we found that the skin phototype IV was
the most common type (45.7%; n = 58). The disease
activity was stable in 27.6%, progressive in 69.3%, and
regressive in 3.1% of the vitiligo patients. Only 52% (n =
66) of them had received a treatment for vitiligo before;
this was in the form of topical treatment in 84.8% (n =
56) and phototherapy in 15.2% (n= 10) of the patients.
Repigmentation was detected after treatment in 31.3%
(n = 40) of the vitiligo patients, and in 15.6% (n= 20) of
the vitiligo patients it was spontaneous. Family history of
vitiligo was reported by 33.9% (n = 43) and family history
of any other autoimmune disease was reported by 29.9%
(n = 38) of the vitiligo patients. (Table 1)
There was at least one concomitant autoimmune
disease in 28.3% (n = 36) of the vitiligo patients. In 8.6%
(n = 11) of the vitiligo patients, there were two additional
autoimmune diseases other than vitiligo. Autoimmune
thyroid disease was the most common autoimmune
disease accompanying vitiligo (18.1%; n = 23) (Table 2).
The study groups were observed to be in the Hardy–
Weinberg equilibrium for SNP1 (P = 0.99, P = 0.65) and
SNP2 (P = 0.78, P = 0.78) for the patients and the controls,
respectively.
We obtained a result for SNP1 in 114 of the patients
and 108 of the controls; and for SNP2 in 98 of the patients
and 85 of the controls. It was shown that, for SNP1, every T
allele addition was significantly associated with 1.53 times
(%95 CI:1.03-2.26) protectiveness in terms of vitiligo
risk (P = 0.033). As for SNP2, every G allele addition
was associated with 1.42 times (%95 CI:0.94-2.16)
protectiveness, which was close to the level of statistical
significance (P = 0.100) (Table 3).
No significant associations were observed between
patient characteristics (disease activity, repigmentation,
stress history at the onset of the disease or before the
exacerbations, concomitant autoimmune disease, family
history of autoimmune disease and vitiligo) and SNPs (all
P-values >0.15)
4. Discussion
In this gene analysis study, our primary aim was to assess the
role of IFIH1 gene locus in GV susceptibility. We detected
an association between IFIH1 gene polymorphisms and
GV susceptibility. We showed that, in terms of vitiligo
development, each T allele is protective for SNP1 and each
G allele is protective for SNP2. These findings reveal that
IFIH1 gene polymorphisms possibly play a role in the
etiopathogenesis of vitiligo.
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Although no relationship was found between family
history and gene polymorphism in our study, since
the reliability of the family history given by the vitiligo
patients was not certain and some of the positive family
history was implying distant relatives, this result might not
be reflecting the actual relationship.
To identify genes involved in susceptibility to GV;
candidate gene association studies, genome-wide linkage
studies and recently genome-wide association studies
(GWASs) have been applied in sequence according to
time. So far, GWASs have discovered approximately 50
different genetic loci that contribute to vitiligo risk, some
of which are shared with other autoimmune disorders that
have epidemiological association with vitiligo (18). One
of these gene loci IFIH1, previously proven to be related
with several autoimmune diseases, was recently defined as
a candidate for susceptibility to GV (1,10,17).
IFIH1 is one of the most significantly associated loci
with vitiligo (1). Several common variants in IFIH1, the
most associated variant being the rs2111485, showed
highly significant association with vitiligo. A missense
variant of IFIH1, rs35667974 (l923V), was reported to
show significant conditional association independent of
rs2111485. All missense variants of IFIH1, i.e. rs1990760
(A946T), rs3747517 (H843R), and rs35667974 (l923V),
showed association with vitiligo in the independent
replication study and the former two showed associations
in all three GWASs (10).
Many vitiligo susceptibility genes that control
immunoregulatory and apoptotic functions are in common
with those that control other autoimmune disorders. These
shared genetic associations are consistent with clinical
epidemiological relations of these disorders (17,18).
IFIH1, together with nsSNP rs1990760, was defined as the
strongest candidate for T1D susceptibility (7). Nejentsev et
al. confirmed the association of the two common missense
polymorphisms, rs1990760 (T946A) and rs3747517
(R843H), with T1D (19). Sutherland et al. confirmed
IFIH1 as a new autoimmunity locus, extending its role
in susceptibility of T1D to Graves’ disease and proposed
that Ala946Thr IFIH1 polymorphism of SNP rs1990760 is
significantly associated with organ-specific autoimmune
diseases, including Graves’ disease (16). Gateva et al.
confirmed the association of the same missense allele
of IFIH1 (rs1990760) with SLE (14). Psoriasis was also
reported to be associated with rare missense variants in
the IFIH1 gene locus (12).
Vitiligo-associated IFIH1 functional variants, missense
SNPs rs1990760 (A946T) and rs3747517 (R843H),
were reported to be protective against T1D in European
individuals (7,9,19). It was proposed that rare alleles of
all associated IFIH1 polymorphisms protect from T1D,
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Table 1. Clinical characteristics of the study subjects.
Clinical characteristics

Vitiligo patients

Controls

n = 127

n = 111

%

Age (years) (mean ± SD)

40.6 ± 16.5

Sex (female/male)
Skin phototype
II
III
IV
Disease activity
stable
progressive
regressive
Treatment history (+/-)

71/56

55.9/44.1 64/47

23
46
58

18.1
36.2
45.7

35
88
4
66/61

27.6
69.3
3.1
52.0/48.0

Family history of autoimmune disease (+/-) 38/89

29.9/70.1

Family history of vitiligo (+/-)

33.9/66.1

Table 2. Distribution
accompanying vitiligo.

43/84

of

%

43.0 ± 17.0

autoimmune

disease

57.7/43.3

types

Autoimmune diseases

n

%

Total

36/127 28.3

Thyroid disease

23

18.1

Pernicious anemia

9

7.0

Alopecia areata

4

3.2

Type 1 diabetes mellitus

3

2.4

Lupus

2

1.6

Bullous pemphigoid

1

0.8

Scleroderma

1

0.8

Lichen planus

1

0.8

Celiac disease

1

0.8

Idiopathic thrombocytopenic purpura 1

0.8

Rheumatoid arthritis

1

0.8

Two different autoimmune diseases

11

8.6

209

ONAN et al. / Turk J Med Sci
Table 3. Estimated risks of vitiligo with the presence of polymorphisms for the two SNPs.

CC (ref.)
CT
TT
CC (ref.)
CT/TT

Case
n=114 (%)
40 (35.1)
57 (50.0)
17 (14.9)
40 (35.1)
74 (64.9)

Control
n=108 (%)
28 (25.9)
54 (50.0)
26 (24.1)
28 (25.9)
80 (74.1)

Recessive

CC/CT (ref.)
TT

97 (85.1)
17 (14.9)

rs2111485

Genotype
AA (ref.)
AG
GG
AA (ref.)
GG/AG
AA/AG (ref.)
GG

rs1990760
Additive
Dominant

Additive
Dominant
Recessive

Genotype

OR

95% (CI)
lower

95% (CI)
upper

P

1.53

1.03

2.26

0.033

1.65

0.91

2.96

0.097

82 (75.9)
26 (24.1)

1.89

0.95

3.74

0.070

Case
n = 98 (%)

Control
n = 85 (%)

OR

95% (CI)
lower

95% (CI)
upper

P

38 (38.8)
45 (45.9)
15 (15.3)
38 (38.8)
60 (61.2)
83 (84.7)
15 (15.3)

25 (29.4)
41 (48.2)
19 (22.4)
25 (29.4)
60 (70.6)
66 (77.6)
19 (22.4)

1.42

0.94

2.16

0.100

1.55

0.83

2.89

0.169

1.67

0.78

3.57

0.183

CI: confidence interval, OR: odds ratios adjusted for age and sex, SNP: single-nucleotide polymorphism.

whereas common IFIH1 alleles create predisposition
to the disease (19). Missense rs1990760 (A946T) was
proposed to be protective against SLE (20), rheumatoid
arthritis (21), multiple sclerosis (10), and Graves’ disease
(16) in the European and other populations. It was shown
that autoimmunity-protective IFIH1 missense variants
decrease function of IFIH1, thus reducing the ability
to bind DAMPs involved in autoimmune triggering
with eventual decreased stimulation of innate immune
responses (9,10,12,22). These missense variants might be
downregulating the gene response by changing the gene
expression.
Genome-wide association studies of vitiligo detected
that the association of IFIH1 functional variants (missense
SNPs rs2111485, rs1990760, rs3747517, rs35667974) was

protective (1,10,17). Similar to the results of these GWAS
studies which were performed in the European population
by Jin et al. (1,10,17), we detected a protective association
of the two functional variants of IFIH1 (rs1990760 and
rs2111485) for vitiligo in the Turkish population. In
conclusion, although the mechanisms by which IFIH1
polymorphisms contribute to vitiligo pathogenesis remain
to be explored, it is clear that the IFIH1 gene locus has a
role in GV susceptibility.
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